Use quotes to search for exact phrases. Use AND/OR/NOT between keywords or phrases for more precise search results.

Maryland Bill Regarding the Administration of Mifepristone (HB 1101)

This law was last updated on Apr 15, 2019


This law is Anti–Choice

State

Maryland

Number

HB 1101

Status

Failed to Pass

Proposed

Feb 8, 2019

Topics

Medication Abortion, Physicians Reporting Requirements, Reporting Requirements

Full Bill Text

mgaleg.maryland.gov

HB 1101 would require the state department of health to adopt certain regulations regarding the administration of mifepristone.

The bill would require mifepristone only be provided by or under the supervision of a physician who:

  • Is able to assess the duration of pregnancy accurately;
  • Is able to diagnose ectopic pregnancies;
  • Is able to provide surgical intervention, and can assure patient access to medical facilities equipped to provide blood transfusions and resuscitation;
  • Has read and understands the prescribing information of mifepristone;
  • Will explain the procedure to each patient;
  • Will provide each patient with a copy of the medication guide and patient agreement regarding mifepristone;
  • Will sign the patient agreement and obtain the patient’s signature;
  • Will notify the sponsor for mifepristone if the treatment procedure doesn’t work;
  • Will report any hospitalization, transfusion, or other serious events to the sponsor; and
  • Will record the mifepristone serial number in each patient’s medical record.

Each provider of mifepristone would be required to:

  • Certify that all the above requirements have been met; and
  • Make the number of administrations of mifepristone, along with the number of adverse reactions, hospitalizations, and complications experienced by individuals due to mifepristone.

A person who violates this provision would be guilty of a misdemeanor and be subject to a $1,000 fine.

The health department would be required to submit a yearly report on the number of administrations of mifepristone by each provider, and the number of adverse reactions, hospitalizations, and complications experienced by individuals due to mifepristone.


Latest Action

2/8/19 – Introduced.


People